CJC-1295 DAC vs ipamorelin explained: how these two growth hormone peptides differ in half-life, receptor targets, dosing frequency, and stacking.
CJC-1295 DAC and ipamorelin both raise growth hormone, but they do it through different receptors and on very different timelines. CJC-1295 DAC is a long-acting GHRH analog that stays active for days, while ipamorelin is a short-acting ghrelin receptor agonist that peaks quickly and clears within about two hours. Most research protocols treat these two peptides as complementary tools rather than substitutes.
How CJC-1295 DAC Works
CJC-1295 DAC is a modified growth hormone-releasing hormone (GHRH) analog. The DAC portion, short for Drug Affinity Complex, lets the peptide bind to albumin in the bloodstream after administration.
That albumin binding is what stretches its half-life from minutes to roughly six to eight days. A single dose can keep growth hormone and IGF-1 elevated for an extended window instead of a brief spike.
The trade-off is a sustained, low-level GH signal rather than a natural pulse. Researchers sometimes refer to this pattern as GH bleed, and it is one reason some protocols choose shorter-acting GHRH analogs instead.
How Ipamorelin Works
Ipamorelin is a pentapeptide that acts as a selective ghrelin receptor (GHS-R1a) agonist. It signals the pituitary to release growth hormone in a pulse that looks closer to the body's own rhythm.
Its half-life is roughly two hours, so effects rise and fall quickly. Ipamorelin is often described as one of the most selective ghrelin-mimetic peptides because it has little measurable effect on cortisol, prolactin, or appetite at the doses commonly used in research.
That selectivity is a major reason ipamorelin appears so often alongside a GHRH analog in laboratory and preclinical work.
CJC-1295 DAC vs Ipamorelin: Side-by-Side Comparison
The table below summarizes the differences that matter most when researchers compare these two compounds.
| Feature | CJC-1295 DAC | Ipamorelin |
|---|---|---|
| Peptide class | Long-acting GHRH analog | Ghrelin receptor agonist (GHRP) |
| Primary receptor | GHRH receptor on the pituitary | GHS-R1a |
| Half-life | About 6 to 8 days | About 2 hours |
| GH release pattern | Sustained elevation | Short pulse |
| Commonly cited research dose | 1 to 2 mg per week | 100 to 300 mcg, 2 to 3 times daily |
| Effect on cortisol and prolactin | Minimal | Minimal at selective doses |
| Appetite stimulation | Little | Less than most other GHRPs |
| FDA approval for human use | None | None |
The biggest practical difference is dosing rhythm. CJC-1295 DAC is administered infrequently, while ipamorelin is given in small, repeated doses to mimic natural pulses.
Why They Are Usually Stacked Instead of Swapped
GHRH analogs and ghrelin receptor agonists hit two separate pathways, and combining them tends to produce a larger GH response than either one alone in preclinical models. That synergy, not competition, is the reason they are so often paired.
Timing is where the pairing gets complicated. Ipamorelin clears in about two hours and is normally dosed two or three times a day, while CJC-1295 DAC is dosed weekly or twice weekly. Matching a fast-pulse peptide with a slow-release GHRH analog is the core of the cjc-1295 with dac vs ipamorelin debate.
For that reason, many protocols pair ipamorelin with the no-DAC version of CJC-1295 instead. The cjc-1295 no dac vs ipamorelin comparison is closer to apples-to-apples because both peptides are short-acting and can be timed together.
People exploring older or more established options sometimes look at sermorelin vs cjc-1295 no dac ipamorelin, since sermorelin is a shorter GHRH fragment with a longer history in clinical research.
Searchers focused on body composition often ask about aod-9604 vs cjc-1295 ipamorelin, even though AOD-9604 targets fat metabolism directly and does not act on the pituitary at all.
Another common query, cjc-1295 ipamorelin vs tesamorelin, contrasts a research stack with the only GHRH analog that holds FDA approval, and that approval is limited to HIV-associated lipodystrophy.
Safety, Legality, and Research Status
CJC-1295 DAC is not FDA-approved for human use in the United States. Ipamorelin is also not FDA-approved for human use in the United States, and both are typically sold as research chemicals intended for laboratory study only.
Because these compounds are not regulated as prescription drugs, product purity and actual content can vary widely between suppliers. Independent testing data is often unavailable, which makes dosing accuracy difficult to verify.
Reported side effects from self-administered peptides include injection-site irritation, fluid retention, joint discomfort, and shifts in blood sugar or IGF-1 levels. Long-term human safety data for either compound is limited, and no large randomized trials support the bodybuilding claims often attached to them.
Anyone weighing the cjc 1295 dac vs ipamorelin question for personal use should treat it as a medical decision and discuss it with a licensed healthcare professional, not as a self-directed protocol.
Key Takeaways
- CJC-1295 DAC and ipamorelin act on different receptors and are not direct equivalents.
- CJC-1295 DAC has a half-life of roughly six to eight days, making it a long-acting option.
- Ipamorelin has a half-life of about two hours, making it a pulsed, selective option.
- Research protocols more often combine a GHRH analog with a ghrelin receptor agonist than pick one over the other.
- Neither peptide is FDA-approved for human use, and both carry unknown long-term risks.
Frequently Asked Questions
What is the main difference between CJC-1295 DAC and ipamorelin?
CJC-1295 DAC is a long-acting GHRH analog with a half-life of roughly six to eight days, while ipamorelin is a short-acting ghrelin receptor agonist that clears in about two hours. They also act on different receptors: CJC-1295 DAC stimulates the GHRH receptor, and ipamorelin targets GHS-R1a. Because of that, they are usually described as complementary rather than interchangeable.
Can you stack CJC-1295 DAC with ipamorelin?
Many research protocols combine a GHRH analog with a ghrelin receptor agonist because the two pathways amplify each other. However, CJC-1295 DAC stays active for days, so pairing it with a peptide normally dosed two or three times daily is less common than using the no-DAC version. Neither compound is FDA-approved, and stacking them does not make them legal or safe for human use.
Is either peptide FDA-approved for human use?
No. CJC-1295 DAC and ipamorelin are both sold as research chemicals and are not FDA-approved for human use in the United States. The only FDA-approved GHRH analog is tesamorelin, and its approval is limited to HIV-associated lipodystrophy. Anyone considering these compounds should talk with a licensed healthcare professional first.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.